Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.
Climent MÁ, Álvarez C, Morales R, Maroto P, Rodríguez-Vida A, Méndez-Vidal MJ, Del Muro XG, Puente J, Láinez N, Vázquez S, Castellano D, Lang CG, Wang J, di Pietro A, Davis C, Sanz-Castillo B, Bolós MV, Valderrama BP. Climent MÁ, et al. Among authors: castellano d. Clin Transl Oncol. 2024 Jun;26(6):1532-1538. doi: 10.1007/s12094-023-03358-4. Epub 2023 Dec 15. Clin Transl Oncol. 2024. PMID: 38102374 Free PMC article. Clinical Trial.
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
Castellano D, del Muro XG, Pérez-Gracia JL, González-Larriba JL, Abrio MV, Ruiz MA, Pardo A, Guzmán C, Cerezo SD, Grande E. Castellano D, et al. Ann Oncol. 2009 Nov;20(11):1803-12. doi: 10.1093/annonc/mdp067. Epub 2009 Jun 23. Ann Oncol. 2009. PMID: 19549706 Free PMC article. Clinical Trial.
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A. Bellmunt J, et al. Among authors: castellano d. Ann Oncol. 2011 Dec;22(12):2646-2653. doi: 10.1093/annonc/mdr023. Epub 2011 Mar 21. Ann Oncol. 2011. PMID: 21427062 Free article. Clinical Trial.
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, González del Alba A, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C. Garcia-Donas J, et al. Lancet Oncol. 2011 Nov;12(12):1143-50. doi: 10.1016/S1470-2045(11)70266-2. Epub 2011 Oct 17. Lancet Oncol. 2011. PMID: 22015057
[Castration-resistant prostate cancer: where are we going?].
Alcaraz A, Medina R, Maroto P, Climent MÁ, Castellano D, Carles J. Alcaraz A, et al. Among authors: castellano d. Actas Urol Esp. 2012 Jun;36(6):367-74. doi: 10.1016/j.acuro.2011.10.010. Epub 2011 Dec 19. Actas Urol Esp. 2012. PMID: 22188754 Review. Spanish.
353 results